Last year was a surprisingly big one for legal decisions impacting the biotechnology transactions and licensing space. Given ...

The Namodenoson oral drug is well positioned in the field of anti-obesity agents due to its activity and favorable safety profile Ramat Gan, ...

In a paper published in Nature Biotechnology, three Stanford University-affiliated co-authors, including Stanford Law School ...

March in rights, i.e. stealing patents, could be exercised by the ... by the U.S. government would be a body blow to the U.S. biotechnology research infrastructure, as no company would partner ...

Patent applications must provide enough detail ... and stay competitive in the rapidly evolving landscape of AI-driven biotechnology. The writer is a patent attorney at Reinhold Cohn Group.

After years of sparring, the Biden administration and Gilead Sciences have settled a contentious lawsuit over patents for a ...

As the above image shows, there's hardly any large pharma/biotech name you can think of that the upcoming patent cliff will spare. Even if some are more exposed than others, almost everybody is ...

Patent-filing research conducted by law firm Withers & Rogers suggests that CAR T-cell therapy capability has reached a pivotal point on route to market, and first-line use of these promising ...

WINT), a biotechnology company focused on advancing early and late-stage innovative therapies for critical conditions and diseases, today announced the issuance of a patent in Japan for “Inhibitors of ...